Our data provide evidence for the novel actions of SGLT2 inhibitors on energy homeostasis and fat accumulation in obesity and suggest their potential therapeutic efficacy in T2DM-associated hepatic steatosis. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.